Logo image of LMNL

LIMINAL BIOSCIENCES INC (LMNL) Stock Fundamental Analysis

NASDAQ:LMNL - Nasdaq - CA53272L2021 - Common Stock - Currency: USD

8.5  +0.01 (+0.12%)

Fundamental Rating

2

Overall LMNL gets a fundamental rating of 2 out of 10. We evaluated LMNL against 551 industry peers in the Biotechnology industry. LMNL may be in some trouble as it scores bad on both profitability and health. LMNL does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

3

1. Profitability

1.1 Basic Checks

LMNL had positive earnings in the past year.
In the past year LMNL has reported a negative cash flow from operations.
In multiple years LMNL reported negative net income over the last 5 years.
In the past 5 years LMNL always reported negative operating cash flow.
LMNL Yearly Net Income VS EBIT VS OCF VS FCFLMNL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 0 -50M -100M -150M -200M

1.2 Ratios

Looking at the Return On Assets, with a value of 1.46%, LMNL belongs to the top of the industry, outperforming 93.73% of the companies in the same industry.
LMNL's Return On Equity of 2.16% is amongst the best of the industry. LMNL outperforms 93.73% of its industry peers.
Industry RankSector Rank
ROA 1.46%
ROE 2.16%
ROIC N/A
ROA(3y)-29.63%
ROA(5y)-80.67%
ROE(3y)-159.64%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
LMNL Yearly ROA, ROE, ROICLMNL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 0 200 -200 -400

1.3 Margins

Looking at the Profit Margin, with a value of 94.11%, LMNL belongs to the top of the industry, outperforming 99.67% of the companies in the same industry.
LMNL does not have Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) 94.11%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
LMNL Yearly Profit, Operating, Gross MarginsLMNL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 0 2K -2K -4K -6K -8K

More info and screens

3

2. Health

2.1 Basic Checks

LMNL does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, LMNL has about the same amount of shares outstanding.
Compared to 1 year ago, LMNL has an improved debt to assets ratio.
LMNL Yearly Shares OutstandingLMNL Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 5M 10M 15M 20M 25M
LMNL Yearly Total Debt VS Total AssetsLMNL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 50M 100M 150M 200M 250M

2.2 Solvency

LMNL has an Altman-Z score of -45.25. This is a bad value and indicates that LMNL is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of LMNL (-45.25) is worse than 95.71% of its industry peers.
A Debt/Equity ratio of 0.02 indicates that LMNL is not too dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.02, LMNL is in line with its industry, outperforming 41.09% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.02
Debt/FCF N/A
Altman-Z -45.25
ROIC/WACCN/A
WACC7.87%
LMNL Yearly LT Debt VS Equity VS FCFLMNL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 0 50M -50M 100M -100M

2.3 Liquidity

LMNL has a Current Ratio of 2.78. This indicates that LMNL is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of LMNL (2.78) is worse than 74.75% of its industry peers.
LMNL has a Quick Ratio of 2.78. This indicates that LMNL is financially healthy and has no problem in meeting its short term obligations.
LMNL has a worse Quick ratio (2.78) than 72.94% of its industry peers.
Industry RankSector Rank
Current Ratio 2.78
Quick Ratio 2.78
LMNL Yearly Current Assets VS Current LiabilitesLMNL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 20M 40M 60M 80M 100M

More info and screens

0

3. Growth

3.1 Past

The earnings per share for LMNL have decreased strongly by -99.10% in the last year.
The Revenue for LMNL has decreased by -12.92% in the past year. This is quite bad
Measured over the past years, LMNL shows a very negative growth in Revenue. The Revenue has been decreasing by -59.99% on average per year.
EPS 1Y (TTM)-99.1%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-53.93%
Revenue 1Y (TTM)-12.92%
Revenue growth 3Y-56.58%
Revenue growth 5Y-59.99%
Sales Q2Q%-28.66%

3.2 Future

Based on estimates for the next years, LMNL will show a very negative growth in Earnings Per Share. The EPS will decrease by -230.98% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-907.27%
EPS Next 2Y-230.98%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
LMNL Yearly Revenue VS EstimatesLMNL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 10M 20M 30M
LMNL Yearly EPS VS EstimatesLMNL Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 0 10 -10 -20 -30

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

Based on the Price/Earnings ratio of 77.27, the valuation of LMNL can be described as expensive.
Based on the Price/Earnings ratio, LMNL is valued cheaper than 93.89% of the companies in the same industry.
When comparing the Price/Earnings ratio of LMNL to the average of the S&P500 Index (27.03), we can say LMNL is valued expensively.
LMNL is expected to report negative earnings next year, which makes the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE 77.27
Fwd PE N/A
LMNL Price Earnings VS Forward Price EarningsLMNL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
LMNL Per share dataLMNL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5 -10

4.3 Compensation for Growth

LMNL's earnings are expected to decrease with -230.98% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-230.98%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

LMNL does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

LIMINAL BIOSCIENCES INC

NASDAQ:LMNL (9/25/2023, 8:00:18 PM)

8.5

+0.01 (+0.12%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-08 2023-08-08/amc
Earnings (Next)11-07 2023-11-07/amc
Inst OwnersN/A
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap19.82M
Analysts43.33
Price Target7.65 (-10%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE 77.27
Fwd PE N/A
P/S 55.26
P/FCF N/A
P/OCF N/A
P/B 1.27
P/tB 1.59
EV/EBITDA N/A
EPS(TTM)0.11
EY1.29%
EPS(NY)-8.96
Fwd EYN/A
FCF(TTM)-11.29
FCFYN/A
OCF(TTM)-11.29
OCFYN/A
SpS0.15
BVpS6.71
TBVpS5.33
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 1.46%
ROE 2.16%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) 94.11%
GM N/A
FCFM N/A
ROA(3y)-29.63%
ROA(5y)-80.67%
ROE(3y)-159.64%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.02
Health
Industry RankSector Rank
Debt/Equity 0.02
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 0.29%
Cap/Sales 0.61%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.78
Quick Ratio 2.78
Altman-Z -45.25
F-Score4
WACC7.87%
ROIC/WACCN/A
Cap/Depr(3y)12.21%
Cap/Depr(5y)35.07%
Cap/Sales(3y)46.16%
Cap/Sales(5y)49.99%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-99.1%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-53.93%
EPS Next Y-907.27%
EPS Next 2Y-230.98%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-12.92%
Revenue growth 3Y-56.58%
Revenue growth 5Y-59.99%
Sales Q2Q%-28.66%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y24.57%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y51.92%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y50.94%
OCF growth 3YN/A
OCF growth 5YN/A